INTRODUCTION
Patients with cancer are at increased risk of developing venous thromboembolism (vte), including deep vein thrombosis (dvt) and pulmonary embolism 1, 2 . Hypercoagulability in this population can occur as a result of cancer treatment (particularly chemotherapy) and of the cancer itself 3, 4 . Compared with patients having local disease, those with metastatic disease have a significantly higher risk of developing vte 5 .
The approximate annual incidence of vte in cancer patients treated with chemotherapy is estimated at 1 in 200; in the general population, the estimate is 117 in 100,000 6 . Importantly, data show that the incidence of vte in cancer patients is on the rise, possibly because of longer survival and the older age of cancer patients 7 . Table i summarizes several patient-, cancer-, and treatment-related factors that adversely affect the risk of vte 8,9 . The risk of dying after an acute thrombotic event is higher by a factor of 4 to 8 in cancer patients than in patients without cancer, and vte is the second-leading cause of non-cancer death in cancer patients [8] [9] [10] [11] [12] [13] .
Although several pharmacologic agents are available to prevent vte, administration of anticoagulants is not always straightforward in the oncology setting. Patients with cancer undergo complex treatment protocols and could have other comorbidities such as renal or hepatic insufficiency and thrombocytopenia that can affect the efficacy and safety of anticoagulation. Several groups have published guidelines on the management of vte in oncology patients-most recently, the American Society of Clinical Oncology 14 and CancerControl Alberta (part of Alberta Health Services) 15 . Other published guidelines include those from the U.S. National Comprehensive Cancer Network 16 , the European Society for Medical Oncology 17 , and the American College of Chest Physicians 18 .
Despite the wealth of guidelines, several key issues surrounding the use of prophylactic anticoagulation and its monitoring in specific subpopulations have not been addressed. Moreover, most of the existing guidelines are largely general oncology guidelines with a subsection on vte. No national guidelines are specifically dedicated to the prophylaxis of cancerassociated vte.
Our overall aim was to develop national recommendations that are evidence-based (or consensusbased where evidence is lacking) on the prevention of vte in patients with cancer. The recommendations are meant to provide guidance to physicians, nurses, and other frontline medical professionals involved in the management of patients with cancer. We address vte prophylaxis in ambulatory, hospitalized, and surgical patients, and the use of anticoagulation in specific clinical scenarios such as renal and hepatic insufficiency, brain metastases, and thrombocytopenia. We also discuss the use of anticoagulation to prolong survival and the monitoring of anticoagulation therapy.
METHODS

Literature Search Strategy
The U.S. National Library of Medicine's PubMed database was searched for relevant articles published between 2002 and March 2013. Search terms included "neoplasm" or "cancer" and "thrombosis prophylaxis" or "vte prophylaxis," and results were limited to randomized controlled trials (rcts) and meta-analyses published between 2008 and March 2013. Trials that did not report outcomes related to the prophylaxis of vte were excluded. In addition, the U.S. National Guidelines Clearinghouse was searched for guidelines published between 2007 and March 2013. Updated results of relevant clinical trials published after March 2013 were also included. Because of a lack of translation services, non-English-language articles were excluded from the review of the evidence.
Development of Recommendations
The development and review process for the recommendations was modelled after these sources: the U.K. National Institute for Health and Clinical Excellence 19 , the Archives of Pediatrics and Adolescent Medicine 20 , and the agree collaboration 21 . Clinical questions and initial recommendations were developed by two medical oncologists (JCE and PK) and a cancer research methodologist (MAS) based on clinical experience and the literature review. The University of Oxford Centre for Evidence-Based Medicine grading system was used to grade the recommendations 22 . Briefly, the levels of evidence were these:
• were further reviewed by a nephrologist and a pharmacist with expertise in renal insufficiency. Recommendations were initially reviewed using a Web-based survey to capture the level of agreement with each statement on a 5-point scale ranging from "strongly agree" to "strongly disagree" and including an option of "unsure." An evidence summary accompanied each statement, and panelists were instructed to consider the level of evidence when rating each statement. In addition to the rating scales, panelists were given the opportunity to comment on each statement. Based on panelist responses, recommendations were categorized as "consensus" (that is, statements with which most panelists agreed, with no more than 3 "neutral" or "unsure" responses allowed) or "nonconsensus" (that is, statements with which at least 1 panelist disagreed or those that had 4 or more "neutral" or "unsure" responses). Non-consensus statements were reviewed once with the entire panel via webinar (Cisco WebEx, San Jose, CA, U.S.A.) to better understand the rationale for any disagreement or uncertainty and to determine where additional discussion was needed to reach consensus. The non-consensus statements were divided into two categories: "monitoring and dosing" and "special populations." Panel members were assigned to working groups to address statements in one of the two categories. Working groups met a final time via webinar to discuss and revise the statements; consensus methods were used.
RESULTS
The literature review identified sixty-five publications, including three clinical practice guidelines. Metaanalyses and rcts were considered strong (higherlevel) evidence in developing the recommendations. Several relevant retrospective case series were also included in the discussion, but were considered to be weak (lower-level) evidence. Based on the Web survey responses, consensus was reached immediately on 15 of the 22 final recommendation statements (68%). The remaining 7 recommendations were further discussed by the assigned panel members to reach consensus. Consensus was eventually reached for all 22 recommendation statements (Table ii) .
DISCUSSION
Patients with active malignancy are at increased risk of vte and increased risk of vte-related mortality 10, 12, 13 . Successful prevention of vte is a high priority, and dvt prophylaxis in the general population has been well established in multiple medical and surgical populations 18 .
Prophylaxis in Ambulatory Cancer Patients
None of the current guidelines recommend routine thromboprophylaxis in ambulatory cancer patients, but all suggest that it be considered for very select high-risk patients 14, 16, 17 . The outpatient prophylaxis score developed by Khorana et al. 4 (Table iii) and validated in randomized trials identifies cancer patients at risk for vte. Anticoagulants tested in cancer patients include dalteparin, enoxaparin, tinzaparin, semuloparin, certoparin, bemiparin, nadroparin, and warfarin [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , of which enoxaparin, dalteparin, and tinzaparin are readily available in Canada. A Cochrane systematic review 43 of 21 rcts that included 9861 ambulatory patients with cancer receiving chemotherapy showed that, compared with inactive control and warfarin, low molecular weight heparin (lmwh) was associated with a 45% reduction in the overall vte incidence [risk ratio: 0.55; 95% confidence interval (ci): 0.34 to 0.88; p < 0.05] and a nonsignificant increase in bleeding. Despite those very interesting findings, which accord with other major guidelines, our consensus was that prophylactic anticoagulation is not advised for all outpatients, but can be used in select cases where indicated.
Prophylaxis in Hospitalized Cancer Patients
Most hospitalized patients with cancer require thromboprophylaxis throughout hospitalization [14] [15] [16] 18 . A systematic review comparing lmwh, unfractionated heparin (ufh), and placebo in medically ill patients (6.7% with current or previous cancer) demonstrated lower rates of dvt with lmwh than with placebo [odds ratio (or): 0.60; 95% ci: 0.47 to 0.75], but no difference when lmwh was compared with ufh (or: 0.92; 95% ci: 0.56 to 1.52). The groups showed no differences in rates of death, vte, or bleeding 44 . The exclaim trial, which compared lmwh (enoxaparin) with placebo in 5963 acutely ill inpatients (1.6% cancer patients), showed a nonsignificant reduction (2.5% vs. 4.0%) in the rate of vte events with lmwh. The rate of major bleeding was slightly higher with lmwh, but not statistically different from the rate with placebo 37 . However, the medenox trial, which compared lmwh (enoxaparin) with placebo in 1102 hospitalized patients, showed a significant reduction in the incidence of vte with lmwh (5.5% vs. 14.9%, p < 0.001) 45 .
The lmwhs have not been compared head-to-head exclusively in cancer patients, but in other populations, no advantages in vte incidence or bleeding rates were observed for any one agent [46] [47] [48] [49] [50] [51] . Unfortunately, a need for cancer-specific dvt prophylaxis trials remains. Recommendations for dvt prophylaxis in cancer inpatients are typically extrapolated from non-cancer-specific dvt prophylaxis trials; only subgroup analyses of non-cancer specific trials are currently available. A meta-analysis by Carrier et al. 52 of all available data on cancer inpatients showed no significant reduction in the occurrence of vte with either lmwh or fondaparinux prophylaxis [relative risk (rr): 0.91; 95% ci: 0.21 to 4.0]. Although dvt prophylaxis is likely effective in cancer populations because of a higher rate of vte, cancer-specific trials are necessary to help select appropriate patients and effective regimens of dvt prophylaxis.
Prophylaxis in Patients Undergoing Cancer Surgery
Consensus recommendations support vte prophylaxis in patients undergoing major cancer surgery.
That consensus is based on the increased risk of vte in patients undergoing surgery that is at least 1 hour in length ( non-cancer-specific trials and were based largely on older data using positive screening radiologic imaging events as an endpoint. The canbesure trial, published in 2010, compared bemiparin with placebo in 625 cancer surgery patients and found that the rate of vte was significantly less in patients treated with bemiparin (0.8% vs. 4.6%, p = 0.01) 29 . The use of anticoagulation in patients undergoing major cancer surgery has been endorsed elsewhere 14 .
Current guidelines recommend extending postoperative prophylaxis for up to 4 weeks in patients undergoing abdominal or pelvic cancer surgery [14] [15] [16] [17] [18] . A meta-analysis comparing the extended use of lmwh (3-4 weeks after surgery) with conventional in-hospital prophylaxis (for the period of time in hospital) evaluated data from patients undergoing major abdominal surgery. The analyzed trials showed that extended prophylaxis significantly reduced the incidence of vte (rr: 0.44; 95% ci: 0.28 to 0.70; p < 0.05), dvt (rr: 0.46; 95% ci: 0.29 to 0.74; p < 0.05), and proximal dvt (rr: 0.24; 95% ci: 0.09 to 0.67; p < 0.05), with no significant differences in major or minor bleeding 54 . Using data from four trials, a Cochrane meta-analysis comparing prolonged lmwh thromboprophylaxis with control treatment or placebo showed that prolonged thromboprophylaxis with lmwh was associated with a 78% lower risk of developing symptomatic vte (or: 0.22; 95% ci: 0.06 to 0.80; p = 0.02) 55 . In both meta-analyses, the trials were non-cancer-specific, and the primary endpoint was positive radiologic screening, with only a few symptomatic events noted.
Currently, only limited data are available from investigations of the role of anticoagulant therapy in patients undergoing low-risk cancer surgery. Risk factors for vte in patients undergoing outpatient surgery include an operative time greater than 120 minutes (or: 1.69; p = 0.027), arthroscopic surgery (or: 5.16; p < 0.001), saphenofemoral junction surgery (or: 13.20; p < 0.001), and venous surgery not involving the great saphenous vein (or: 15.61; p < 0.001) 56 . However, data on the use of anticoagulation in those patients are lacking.
Preferred Prophylactic Therapy
The preferred anticoagulation therapy in the prophylactic setting is lmwh. There are no clinical data comparing tinzaparin, enoxaparin, and dalteparin in the prophylactic setting in patients with active malignancy, patients undergoing non-orthopedic surgery, or acutely ill patients. Based on data from hospitalized non-cancer patients indicating similar efficacy and bleeding rates [47] [48] [49] [50] , it is reasonable to suggest that no particular lmwh is superior to another in that setting. Dalteparin is typically dosed subcutaneously at 5000 U daily 25, 27 . Enoxaparin is typically dosed subcutaneously at 40 mg daily or, in patients with severe renal impairment, at 30 mg daily 35, 37, 38, 57 . Tinzaparin is typically dosed subcutaneously at 4500 U daily or 75 U/kg daily 58 .
Prophylaxis in Special Clinical Scenarios
4.5.1
Patients with a Central Venous Catheter The role of anticoagulation in the prevention of central venous catheter (cvc)-related thrombosis has been investigated 39, 59 . Although anticoagulants have been shown not to increase the risk of bleeding, three systematic reviews and a meta-analysis failed to show that they lower the incidence of symptomatic cvc-related thrombosis [60] [61] [62] [63] . Thromboprophylaxis for a cvc is therefore not recommended 14-17 .
Patients with Renal Insufficiency
In patients with impaired renal function (creatinine clearance ≤ 30 mL/min), lmwh can accumulate as a result of reduced excretion, which could result in an increased risk of bleeding. Prophylactic lmwh should therefore be used with caution in patients with renal impairment 64 . Tinzaparin has the highest average molecular weight (6500 Da) of the available lmwhs, followed by dalteparin (6000 Da). Enoxaparin (4500 Da) is the smallest and most renal-dependent lmwh. In contrast, by virtue of its larger size, tinzaparin appears to be less dependent on renal clearance and more dependent on the reticuloendothelial system 65 . Tinzaparin might therefore be preferable in patients with renal insufficiency.
4.5.3
Elderly Patients There are limited data and no rcts comparing tinzaparin, enoxaparin, and dalteparin with each other or with ufh or coumadin in elderly patients with cancer. The direct study included critically ill patients (n = 138) with a creatinine clearance less than 30 mL/ min given dalteparin (5000 IU daily) in the prophylactic setting. Bioaccumulation (that is, a factor Xa level > 0.40 IU/mL) was observed in no patients (0%; 95% ci: 0% to 3.0%) and the median trough level of factor Xa was below the detectable limit (<0.10 IU/ mL) 66 . A rct that enrolled patients with a median creatinine clearance of 34.7 ± 11.4 mL/min randomized to enoxaparin (40 mg) or to tinzaparin once daily in the prophylactic setting found that factor Xa did not accumulate significantly for tinzaparin, but did accumulate for enoxaparin (p < 0.0001) 67 . None of the available data are cancer-specific.
Patients with Thrombocytopenia
No trials have evaluated bleeding risk relative to platelet count in any population of patients requiring prophylactic anticoagulation. In general, thrombocytopenic patients are excluded from anticoagulation trials. Expert opinion would suggest that the bleeding risk is negligible in patients with an isolated thrombocytopenia when platelets number 50,000/μL or more; however, spontaneous bleeding, including fatal intracranial hemorrhage, is typically felt to be more relevant in patients with a platelet count below 20,000/μL. The American Society of Clinical Oncology guidelines do not recommend prophylaxis with anticoagulants in patients with a platelet count below 50,000/μL 14 , but many experts in the field suggest that prophylactic anticoagulation can rationally be used for specific patients with platelet counts as low as 20,000/μL [68] [69] [70] . In such situations, we recommend consultation with thrombosis experts.
4.5.5
Patients with Central Nervous System Malignancy Anticoagulation is acceptable in patients with central nervous system malignancies, but should be provided at the discretion of the treating physician. The prodige trial randomized 186 adults with malignant glioma to subcutaneous dalteparin (5000 U) or to placebo once daily and reported no difference in the incidence of vte in the first 6 months (9.1% vs. 14.9% respectively; hazard ratio: 0.51; 95% ci: 0.19 to 1.4; p = 0.29). Major bleeding at 12 months was also not significantly different (5.1% vs. 1.2%, p = 0.22) 25 . A retrospective series of 40 newly diagnosed patients with grade 3 or 4 malignant glioma initiated on a prophylactic dose of daily tinzaparin between 48 hours and 4 weeks postoperatively for a planned duration of 12 months reported grade 4 or 5 central nervous system hemorrhages or grade 2 or greater systemic hemorrhages. Of the 40 patients, 1 developed a dvt while taking tinzaparin, and 3 developed thromboembolic complications while off tinzaparin 58 . Similar findings from retrospective reviews of bleeding events have been reported elsewhere in patients with central nervous system malignancy receiving prophylactic anticoagulation 71, 72 .
4.5.6
Obese Patients Patients with a body mass index greater than 30 kg/m 2 are considered to be obese 73 , and the anticoagulation needs of most patients in that range will exceed the highest prefilled syringes of lmwh. A prospective comparison of three enoxaparin dosing regimens for dvt prophylaxis in 531 medically ill patients with extreme obesity (>40 kg/m 2 ) showed that peak factor Xa levels were significantly higher in the higher weight-based dose group (enoxaparin 0.5 mg/kg daily) than in the lower weight-based dose group (enoxaparin 0.4 mg/ kg daily) or in the fixed-dose group (40 mg daily). Compared with the lower weight-based dose or fixeddose groups, the higher weight-based dose group more frequently achieved target factor Xa levels (p < 0.05). No adverse event (bleeding, thrombosis) occurred in any group 74 .
Weight-adjusted tinzaparin and dalteparin dosing showed a predictable response regardless of body weight or body mass index, without a need for maximal absolute dose capping 75, 76 . Given that no available data suggest increased bleeding rates or other toxicities at higher lmwh doses in obese patients, the consensus recommendation is to avoid dose-capping or the use of ideal body weight for dose calculations; for all lmwhs, use the actual weight-based dose.
New Oral Anticoagulants
Novel direct oral anticoagulants that have been developed include factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and thrombin inhibitors (dabigatran). Some of these agents have completed phase iii trials in dvt prophylaxis after hip and knee replacement surgery and for medically ill patients [77] [78] [79] . However, data for cancer-specific populations in those studies are lacking. Data are limited mostly to post hoc analyses of subgroups, which typically constituted only about 5% of the total study population. In addition, variable definitions of cancer were used in each trial, many of which did not reflect accepted definitions of active cancer.
Cancer subgroups from the dvt prophylaxis trials showed a concerning trend toward no efficacy, but increased rates of major bleeding. Compared with a parenteral agent, oral agents could be disadvantaged in patients at increased risk of gastrointestinal dysfunction (because of nausea, vomiting, and so on), altered absorption patterns, and drug interactions. All of those limitations highlight the need for more high-quality cancer-specific clinical trials before novel direct oral anticoagulants can be endorsed. Use of such agents is not recommended for cancerassociated thromboprophylaxis.
Anticoagulation to Improve Overall Survival
It is not recommended that anticoagulation be used to extend survival in patients with cancer in the absence of other indications for anticoagulation 14 patients. A meta-analysis of 3343 patients from eleven studies of ufh (one trial), lmwh (six trials), and warfarin (four trials) compared anticoagulation treatment with no anticoagulation or placebo for primary vte prophylaxis. The results showed a lower risk of mortality that was statistically significant for lmwh (p = 0.015), but not for ufh (p = 0.095) or warfarin (p = 0.239). With all anticoagulant options, the rate of major bleeding was observed to be increased (p < 0.0001), although the increase was not significant for lmwh on its own (p = 0.128) 80 . Notably, more than half the included trials had been published more than 15 years earlier.
Two Cochrane reviews of clinical trials assessed cancer survival with the addition of oral anticoagulation (six trials with warfarin, one trial with apixaban) 81 or parenteral anticoagulation (one trial with ufh, eight trials with lmwh; 2857 participants in total) 82 compared with no anticoagulation or placebo. At 1 year, no mortality benefit was observed for ufh and lmwh; however, at 2 years, a statistically significant mortality benefit emerged (rr: 0.79; 95% ci: 0.67 to 0.93). Major bleeding was increased (rr: 1.30; 95% ci: 0.59 to 2.88), and the difference was statistically significant. Despite those interesting observations, many of the available studies were published more than 15 years ago, included small numbers of patients or represented subgroup or post hoc analyses, or did not focus on survival as the primary outcome. The cancer types studied were also limited, and so results might not apply broadly. Finally, major bleeding rates were uniformly elevated. Until more rigorous randomized trials using modern cancer therapies and anticoagulation regimens are conducted in future, anticoagulation to extend survival in patients with cancer is not recommended 83 .
SUMMARY
This is the first national Canadian guideline on the prophylaxis of vte in cancer patients. Patients with cancer are at increased risk of vte. Prophylactic antithrombotic therapy with lmwh can greatly reduce the risk of vte, particularly for hospitalized cancer patients. Some subgroups of patients with cancer, including those with thrombocytopenia, renal insufficiency, and obesity might require modifications of the anticoagulant regimen. Use of direct oral anticoagulants for prophylaxis is not supported at the present time.
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